These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 29602702)
1. Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups. Latsuzbaia A; Arbyn M; Weyers S; Mossong J Vaccine; 2018 Apr; 36(18):2411-2416. PubMed ID: 29602702 [TBL] [Abstract][Full Text] [Related]
2. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges. Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574 [TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccine introduction--the first five years. Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of bivalent and quadrivalent human papillomavirus vaccination in Luxembourg. Latsuzbaia A; Arbyn M; Tapp J; Fischer M; Weyers S; Pesch P; Mossong J Cancer Epidemiol; 2019 Dec; 63():101593. PubMed ID: 31499377 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage. Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625 [TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016. Gallagher KE; Howard N; Kabakama S; Mounier-Jack S; Burchett HED; LaMontagne DS; Watson-Jones D Papillomavirus Res; 2017 Dec; 4():72-78. PubMed ID: 29179873 [TBL] [Abstract][Full Text] [Related]
7. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database. Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386 [TBL] [Abstract][Full Text] [Related]
8. Correlates of human papillomavirus vaccine coverage: a state-level analysis. Moss JL; Reiter PL; Brewer NT Sex Transm Dis; 2015 Feb; 42(2):71-5. PubMed ID: 25585064 [TBL] [Abstract][Full Text] [Related]
9. Safety of HPV vaccines in the age of nonavalent vaccination. Quattrone F; Canale A; Filippetti E; Tulipani A; Porretta A; Lopalco PL Minerva Pediatr; 2018 Feb; 70(1):59-66. PubMed ID: 29363293 [TBL] [Abstract][Full Text] [Related]
10. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299 [TBL] [Abstract][Full Text] [Related]
11. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524 [TBL] [Abstract][Full Text] [Related]
12. Identification of determinants associated with uptake of the first dose of the human papillomavirus vaccine in Denmark. Amdisen L; Kristensen ML; Rytter D; Mølbak K; Valentiner-Branth P Vaccine; 2018 Sep; 36(38):5747-5753. PubMed ID: 30111513 [TBL] [Abstract][Full Text] [Related]
13. Social determinants of community-level human papillomavirus vaccination coverage in aschool-based vaccination programme. Jean S; Elshafei M; Buttenheim A Sex Transm Infect; 2018 Jun; 94(4):248-253. PubMed ID: 29330310 [TBL] [Abstract][Full Text] [Related]
14. Human Papillomavirus Vaccination in Washington State: Estimated Coverage and Missed Opportunities, 2006-2013. Oltean HN; Lofy KH; Goldoft MJ; DeBolt CA Public Health Rep; 2016; 131(3):474-82. PubMed ID: 27252567 [TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2013 Jul; 62(29):591-5. PubMed ID: 23884346 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Poljak M Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799 [TBL] [Abstract][Full Text] [Related]
17. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Cuschieri K; Kavanagh K; Moore C; Bhatia R; Love J; Pollock KG Br J Cancer; 2016 May; 114(11):1261-4. PubMed ID: 27115467 [TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599 [TBL] [Abstract][Full Text] [Related]
19. Adolescent human papillomavirus vaccination in the United States: Opportunities for integrating pharmacies into the immunization neighborhood. Fava JP; Colleran J; Bignasci F; Cha R; Kilgore PE Hum Vaccin Immunother; 2017 Aug; 13(8):1844-1855. PubMed ID: 28605256 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]